Estudo observacional no Catar: Vacina da Pfizer–BioNTech se mostrou 89,5% eficaz contra a variante B.1.1.7 e 75% eficaz contra a variante B.1.351. A eficácia da vacina contra doença grave, crítica ou fatal com qualquer variante do SARS-CoV-2 foi de 97,4%.

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants – New England Journal of Medicine

Comentário: Pfizer-BioNTech vaccine offers strong protection against key variants of concern, real-world data from Qatar shows – The Washington Post

Comentário no Twitter

📍GET BOTH DOSES! Great variants & #COVID19 vaccine news—Pfizer/BioNTech vaccine had great efficacy of 89.5% vs #B117 🇬🇧 variant & 75% vs #B1351 🇿🇦 variant for infection—but only with 2 doses. The 1 dose efficacy was just ~29% vs #B117 & ~17% vs #B1351. 🧵https://t.co/SprUfggnmh pic.twitter.com/VDWHiLsQLL

— Eric Feigl-Ding (@DrEricDing) May 6, 2021